Skip to main content
Download PDF

Salivary level of microRNA-146a and microRNA-155 biomarkers in patients with oral lichen planus versus oral squamous cell carcinoma

BMC Oral Health volume 23, Article number: 433 (2023) Cite this article

Abstract

Background

Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa, which has potential for malignant transformation. MicroRNAs play an important role in immunopathogenesis of OLP, and may be used for prediction of its malignant transformation. This study aimed to assess the salivary level of microRNA-146a and microRNA-155 biomarkers in patients with OLP and oral squamous cell carcinoma (OSCC).

Methods

In this case-control study, unstimulated saliva samples were collected from 60 patients, including 15 patients with dysplastic OLP, 15 OLP patients without dysplasia, 15 patients with OSCC, and 15 healthy controls according to the Navazesh technique. After RNA extraction, the expression of microRNA-146a and microRNA-155 was quantified by real-time quantitative polymerase chain reaction (RT-qPCR). The data were analyzed by the Kruskal-Wallis and Dunn-Bonferroni tests.

Results

The difference in expression of microRNA-146a and microRNA-155 among the four groups was significant (P < 0.05). Pairwise comparisons of the groups showed significantly higher expression of microRNA-146a in OLP (P = 0.004) and dysplastic OLP (P = 0.046) patients compared with the control group. Up-regulation of this biomarker in OSCC patients was not significant compared with the control group (P = 0.076). Up-regulation of micro-RNA-155 was only significant in OLP group, compared with the control group (P = 0.009). No other significant differences were found (P > 0.05).

Conclusion

Considering the altered expression of MicroRNA-146a and microRNA-155 in dysplastic OLP and OSCC, their altered expression may serve as an alarming sign of malignancy. However, further investigations are still required.

Peer Review reports

Introduction

Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa, which has different clinical manifestations. OLP is more common in middle-aged women and has a prevalence of 0.1–2.2% in the general population. Its potential for malignant transformation is reportedly 1–2% annually [1]. There are some controversies about malignant transformation risk factors in patient OLP, some of these risk factors are tobacco, alcohol, clinical form, or intraoral localizations of OLP [1].

Although the role of cell-mediated immunity through the T-lymphocytes in development of OLP has been previously confirmed, the exact etiology of OLP has not yet been clearly understood. Evidence shows that stress, genetics, and infections may play a role in development of OLP [2].

OLP has a wide range of clinical manifestations, and its diagnosis based on the clinical criteria is possible. However, histopathological diagnosis is imperative for the atrophic and erosive types, due to their potential for malignant transformation [3]. Controversy exists regarding the malignant transformation potential of OLP. However, at present, OLP is generally considered as a lesion with potential for malignant transformation [2].

Evidence shows that micro ribonucleic acids (microRNAs) play an important role in immunopathogenesis of OLP, and may be used for prediction of its malignant transformation. MicroRNAs play a pivotal role in regulation of the immune function and prevention of autoimmune diseases. They are single-stranded non-coded 18 to 25-nucleotide small molecules that regulate post-transcriptional gene expression by targeting the 3-untranslated area of the messenger RNAs (mRNAs) to down-regulate or stop the process of transcription. Gene regulation mediated by microRNAs is critical for the normal cell functions such as cell mitosis, differentiation, and apoptosis such that in one-third of human mRNAs, post-transcriptional gene expression is controlled by epigenetics [4,5,6].

It has been shown that CD8 + cytotoxic T cells play a role in development of OLP by degeneration of oral epithelial basal layer cells [7]. Also, immune and inflammatory factors and cytokines such as interferon-gamma and tumor necrosis factor-alpha play important roles in development of OLP. MicroRNAs have a close correlation with cytokines in different inflammatory conditions. Some changes in the expression of microRNAs are associated with chronic inflammatory processes and malignant transformation in oral precancerous conditions [6].

Considering the over-expression of microRNA-146a and microRNA-155 in cancerous lesions, they may be able to serve as efficient biomarkers for assessment of possible carcinogenesis. MicroRNA-155 is encoded by the MIR-155 gene, which is localized to the human chromosome band 21q21.3. This miRNA is processed from an exon of the non-coding RNA known as BIC [4]. MicroRNA-155 has numerous applications, and is closely correlated with inflammation and immune system regulation. According to some studies, microRNA-155 is a strong biomarker related to OLP [4, 8]. Altered expression of microRNA-155 is believed to have a significant effect on the biological properties of lymphocytes [9]. Rather et al. evaluated tissue specimens of oral squamous cell carcinoma (OSCC) patients and showed that oncogenic activity of micro-RNA-155 decreased the activity of tumor suppressor CDC73 and increased the risk of OSCC as such [10]. MicroRNA-146a, as an inhibitor of Th1-cell differentiation in human T cells acting via targeting the protein kinase C epsilon (PRKCε), which is part of a functional complex consisting of STAT4 and PRKCε, controls Th1-cell differentiation in human CD4 + T lymphocytes [11]. Also, recent evidence showed that micro-RNA-146a had an important role in inflammatory diseases and regulation of T-lymphocytes [11]. Similarly, some other studies showed over-expression of microRNA-146a in tissue samples of OSCC patients [12, 13]. This over-expression was also noted in metastatic lesions [14]. Huffaker et al. indicated the involvement of microRNA-146a and mciroRNA-155 in regulation of the immune response [15]. These two microRNAs appear to have opposite effects on inflammation since microRNA-155 induces T-lymphocytes, while mciroRNA-146a inhibits T-lymphocytes; they have mutual effects as well [15]. However, some others reported no correlation between them [16]. In OLP patients, in particular, the expression of microRNA-146a and microRNA-155 increases in peripheral blood mononuclear cells [5, 8].

Saliva samples can be used for measurement of biomarkers since saliva reflects the body status and can be used for diagnostic purposes [17]. Arantes et al. demonstrated that microRNAs can be used as diagnostic biomarkers for detection of cancer due to their specific expression in some tumors, and stability in tissues, blood circulation, and body fluids [18]. Saliva can serve as a source of molecular and microbial information and may reveal the presence of a disease condition [18]. Use of salivary biomarkers has been suggested as a reliable non-invasive modality for early detection of OSCC, and can serve as a suitable alternative to invasive biopsy techniques, which is currently the only way for diagnosis of oral cancer in primary stages.

Considering the increasing prevalence of risk factors related to oral cancer [19], and the rising rate of cancer-related morbidity and mortality in Iran, cancer prevention and control is currently a priority, and primary screening of high-risk populations is imperative [20]. Concerning the close relationship of microRNA-155 and microRNA-146a with the immune system, and the variations in the immune system function in different races [21], this study aimed to assess the salivary level of microRNA-146a and microRNA-155 biomarkers in patients with OLP and OSCC.

Materials and methods

This case-control study was conducted on 15 OLP patients with dysplasia, 15 OLP patients without dysplasia, 15 patients with OSCC, and 15 healthy controls. The study protocol was approved by the ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.DRC.REC.1399.044).

The sample size was calculated to be 15 in each group according to a previous study [22] assuming the effect size of 0.45, alpha = 5%, and power of 80% using ANOVA fixed effect model of G Power. Thirty patients with clinical manifestations of OLP were selected and underwent incisional biopsy to assess the trend of microscopic cellular changes in them. Fifteen OSCC patients were also selected among those presenting to the Oral Medicine Departments of School of Dentistry, Shahid Beheshti University of Medical Sciences and Cancer Institute of Imam Khomeini Hospital after excisional biopsy and histopathological confirmation. Fifteen age- and sex-matched healthy controls with no history of oral lesions or systemic diseases were also included. Finally, due to the coronavirus disease 2019 pandemic, 15 non-dysplastic OLP, 8 dysplastic OLP, and 4 OSCC cases from the study by Mehdipour et al. [22] were also included in this study after gaining permission. The samples had been stored at -80 °C in RNAlater storage solution (Sigma Aldrich, Merck, Germany) [23]. The remaining samples were collected according to the criteria mentioned in a similar previous study [22].

Gender, age, type and manifestations of lesion, location of lesion, duration of involvement, and the existing signs and symptoms were all recorded.

After ensuring no involvement of the skin and genital mucosa and no other malignancy, autoimmune diseases, immunodeficiency, hepatitis, HIV infection, or cardiovascular disease, no smoking and alcohol consumption, and no other oral lesion or periodontitis, written informed consent was obtained from all patients to use their information and biopsy samples for research purposes. A total of 60 patients, including 15 OLP patients with histopathological diagnosis of dysplasia (with different grades), 15 patients with histopathologically confirmed OLP without dysplasia, 15 patients with histopathologically confirmed OSCC, and 15 healthy controls were enrolled. In order to check the presence or absence of dysplasia, patients with OLP were subjected to incisional biopsy from the erosive, ulcerative, and plaque-like areas in which dysplasia is more likely than other areas [22]. The incisional biopsy samples of OLP patients were independently evaluated by two oral and maxillofacial pathologists, and those results suggestive of OLP, and early invasive SCC were excluded.

Saliva collection

Unstimulated saliva samples were collected from the participants between 8 a.m. to 13 p.m. by the Navazesh technique [24]. According to this technique, the patients were requested to refrain from eating, drinking, and oral hygiene measures (toothbrushing or use of mouthwash) for at least 1 h prior to saliva sampling. The participants were requested to rinse their mouths and then spit into a 15-mL RNase-free Falcon tube in a seated position within 30 min until 3–5 ml of saliva was collected. Next, 1 mL of RNAlater (Sigma Aldrich, Merck, Germany) was added to the samples and they were stored at -80 °C until RNA extraction [22].

RNA extraction

After removing from the freezer, the saliva samples were centrifuged at 2000 rpm at 4 °C for 20 min to remove debris and floating cells. The transparent supernatant was collected by a 1000-landa (µL) sampler and transferred into a 1.5 µL tube; 1 mL of RNX (Trizol; Anacell Teb, Tehran, Iran) was added to it and pipetted by a sampler. The microtubes were vortexed for 5–10 s and kept at room temperature for 5 min; 200 µL of chloroform was added, manually mixed for 15 s, and placed on ice for 10 min. Next, they were centrifuged at 12,000 rpm at -4 °C. The aqueous phase was removed by a sampler and transferred into a new RNase and DNase-free microtube. Isopropanol was added in an amount equal to the aqueous phase and gently mixed manually. To enhance the deposition of sediment, it was refrigerated at -20 °C overnight. Next, it was centrifuged again at 12,000 rpm at -4 °C. The supernatant was discarded, 1 mL of 75% ethanol was added to the microtube and shortly vortexed. It was then centrifuged at 7500 rpm at -4 °C for 8 min. The supernatant was discarded until the microtube was completely dried. Next, DEPC was dissolved in 20 µL of distilled water. Thermo Scientific NanoDrop One was used to ensure the purity of RNA. The RNA ratios (260/280) were reported in nanograms per microliter (ng/µL).

Complementary DNA (cDNA) synthesis from RNA

The cDNA required for real-time quantitative polymerase chain reaction (RT-qPCR) was synthesized from the extracted RNA using a cDNA synthesis kit (Anacell Teb, Tehran, Iran) according to the manufacturer’s instructions. All steps of the procedure were performed on ice under a laminar hood in sterile conditions. A specific primer designed by the stem-loop technique was used for this purpose. To prepare the RNA stock solution for cDNA synthesis, the RNA was defrosted and the followings were mixed: 0.5 µL RT primer, 1.125 µL RNA, 0.125 µL dNTP Mix (10 mM each), 0.125 µL RNase Inhibitor (20 U/µl), 0.125 µL ExcelRT™ Reverse Transcriptase (200 U/µl), and 0.5 µL RT Buffer 5X, yielding a total volume of 2.5 µL. In the next step, 2 µL of the stock solution was added to 0.2 RNase and DNase-free Microtubes, and 0.5 µL primers of each gene added to it. The microtube containing the template, primer, enzyme and buffer was placed in a thermocycler (PEQ Star) for cDNA synthesis. The thermal protocol was as follows: 30 min at 16 °C, 30 min at 42 °C, and 5 min at 85 °C.

RT-qPCR

The synthesized cDNA was mixed with SYBER Green master mix (Anacell Teb) and specific primers for each microRNA in 0.1 µL microtube in a metal rack. U6 gene was used as the internal control and housekeeping gene. RT-qPCR was performed as duplicate for each sample with one cycle of denaturation and 40 cycles of amplification using real-time PCR device (Roche, Switzerland) according to the manufacturer’s instructions. The thermal protocol for PCR was as follows:

Hold: 15 min at 95 °C to activate DNA Tag polymerase.

Cycling: 15 s at 95 °C for DNA denaturation.

Annealing: 60 s at 60 °C for annealing.

Statistical analysis

Data were analyzed using SPSS version 25 (IBM Co., Armonk, NY, USA). The frequency, percentage, mean, standard deviation, median, and interquartile range were reported in the descriptive data. Since the data were found to have non-normal distribution, the Kruskal-Wallis test was used to compare the four groups regarding the expression of microRNA-146a and microRNA-155. The Dunn-Bonferroni test was applied for pairwise comparisons of the groups. P < 0.05 was considered statistically significant.

Results

Thirty OLP patients were evaluated. One patient was excluded from the dysplastic OLP group due to saliva sample inadequacy. Of 15 non-dysplastic OLP patients, 11 were females and 4 were males. Of 15 dysplastic OLP patients, 10 were females and 5 were males. Of 15 OSCC patients, 9 were males and 6 were females.

The mean age was 40 ± 14 years in the control group, 52 ± 16 years in non-dysplastic OLP group, 54 ± 12 years in the dysplastic OLP group, and 50 ± 14 years in the OSCC group.

Location of the lesion was widely variable in the oral cavity of patients.

Histopathological assessment of biopsy specimens and their re-evaluation by another pathologist showed no evidence of malignancy in 15 patients with non-dysplastic OLP (Fig. 1). In 15 dysplastic OLP patients, dysplastic changes were noted; out of which, 7 had mild dysplasia (42.85%, Figs. 2), 4 had mild to moderate dysplasia (28.57%), 3 had moderate dysplasia (21.42%, Fig. 3), and 1 had severe dysplasia (7.14%, Fig. 4). The cases with lichenoid dysplasia were excluded. Figure 5 shows histopathological micrograph of an OSCC patient.

Fig. 1
figure 1

Histopathological micrograph of non-dysplastic OLP (x100 magnification)

Full size image
Fig. 2
figure 2

Histopathological micrograph of OLP with mild dysplasia (x100 magnification)

Full size image
Fig. 3
figure 3

Histopathological micrograph of OLP with moderate dysplasia (x100 magnification)

Full size image
Fig. 4
figure 4

Histopathological micrograph of OLP with severe dysplasia (x100 magnification)

Full size image
Fig. 5
figure 5

Histopathological micrograph of OSCC (x100 magnification)

Full size image

MicroRNA-146a

The Kruskal-Wallis test showed a significant difference in expression of microRNA-146a among the four groups (P = 0.013). Pairwise comparisons by the Dunn-Bonferroni test showed minimum expression of microRNA-146a in healthy controls. The maximum expression of this biomarker was noted in non-dysplastic OLP group with a significant difference with healthy controls (P = 0.004). Also, the expression of this biomarker was significantly higher in dysplastic OLP compared with the control group (P = 0.046). No other significant differences were noted (P > 0.05, Table 1; Fig. 6).

Table 1 Pairwise comparisons of the groups regarding the expression of microRNA-146a
Full size table
Fig. 6
figure 6

The average expression level of microRNA-146a in different groups with a 95% confidence interval

Full size image

MicroRNA-155

The Kruskal-Wallis test showed a significant difference in expression of microRNA-155 among the four groups (P = 0.045). Pairwise comparisons by the Dunn-Bonferroni test showed minimum expression of microRNA-155 in healthy controls. Maximum expression of this biomarker was noted in OLP patients with a significant difference compared with healthy controls (P = 0.009). No other significant differences were noted (Table 2; Fig. 7).

Assessment of the expression of microRNAs in males and females and in those under and over 40 years of age revealed no significant difference (P > 0.05).

Table 2 Pairwise comparisons of the groups regarding the expression of microRNA-155
Full size table
Fig. 7
figure 7

The average expression level of microRNA-155 in different groups with a 95% confidence interval

Full size image

Discussion

This study assessed the salivary level of microRNA-146a and microRNA-155 biomarkers in patients with OLP and OSCC. The results showed that the difference in expression of microRNA-146a and microRNA-155 among the four groups was significant (P < 0.05). Pairwise comparisons of the groups showed significantly higher expression of microRNA-146a in OLP (P = 0.004) and dysplastic OLP (P = 0.046) patients compared with the control group. Up-regulation of this biomarker in OSCC patients was not significant compared with the control group (P = 0.076). Up-regulation of micro-RNA-155 was only significant in OLP group, compared with the control group (P = 0.009). No other significant differences were found (P > 0.05). Expression of microRNA had no significant correlation with age or gender. A similar previous study found no significant correlation between age and gender and expression of microRNAs either [25].

Altered expression of microRNAs in the serum, blood, plasma, and saliva samples of patients with head and neck cancer as potential biomarkers with minimal invasion for early detection or determination of prognosis of patients has recently gained the spotlight [26]. Recent studies have focused on the role of microRNAs in the pathogenesis and severity of OLP [8, 27]. However, they mainly assessed the tissue and serum samples of OLP patients [16].

The accuracy and feasibility of the assessment of microRNAs in the saliva of OSCC and OLP patients have been previously documented [28]. Thus, the expression of microRNA-155 and microRNA-146a in the saliva samples of OLP and OSCC patients was evaluated in the present study.

Over-expression of microRNA-146a in OLP patients indicates the involvement of this microRNA in pathogenesis of OLP. The present results were in line with previous findings that showed over-expression of microRNA-146a in OLP patients compared with healthy controls [4]. Also, altered expression of this biomarker has been reported in other inflammatory and autoimmune diseases [29,30,31]. Liang et al. evaluated the expression of microRNA-155, microRNA-146a, and microRNA-146b in peripheral blood mononuclear cells and tissue specimens of OLP patients and healthy controls [27]. They also analyzed the correlation of microRNA expression and clinical features of OLP. The results of RT-PCR showed that the expression of microRNA-155 in peripheral blood mononuclear cells of OLP patients was significantly higher than that in controls. Also, the expression of microRNA-146a in OLP patients was significantly higher than that in controls, which was in line with the present results. However, in contrast to the present findings, they found no significant difference in expression of microRNA-146a in peripheral blood mononuclear cells between the OLP and control groups. This difference may be due to the assessment of extracellular compared with intracellular microRNAs. A recent study used Western blotting and RT-qPCR and showed elevated expression of microRNA-146a in Treg cells, and increased proliferation and apoptosis of cells in OLP [32]. These results obtained by assessment of tissue specimens were in agreement with the present results obtained by assessment of saliva samples of patients. This similarity may be explained by the role of microRNA-146a in the process of inflammation and T-cell-mediated immunity in OLP [11].

Liu et al. evaluated the expression of microRNA-146a in peripheral blood CD4 + T-cells and local OLP lesions, and its association with clinical presentation of OLP using RT-PCR [33]. They found no significant difference in expression of microRNA-146a by the peripheral blood CD4 + T-cells between the OLP and control groups, which was different from the present findings. This difference may be due to the fact that they analyzed serum samples while we assessed the saliva samples.

Several studies have shown alterations in expression of microRNA-155 in OLP patients. Similar to the present findings, Liu et al. [33] reported an increase in expression of microRNA-155 in peripheral blood mononuclear cells and OLP lesions in OLP patients compared with healthy controls. Moreover, they demonstrated that the expression of microRNA-155 was significantly correlated with disease severity. Nonetheless, in-depth studies on the mechanisms of involvement of microRNA-155 in OLP are limited. As mentioned earlier, immune factors play important roles in pathogenesis of OLP. MicroRNA-155 is closely correlated with the immune system regulation [8], which may explain its over-expression in OLP, as indicated in the present study. Also, microRNA-155 is the first microRNA that was recognized as an oncogene [34]. Its over-expression has been reported in different cancer types such as the breast cancer, colon cancer, cervical cancer, and lung cancer. This particular microRNA is pivotal for tumor development, and mainly serves as a tumorigenic factor [35].

Lerner et al. evaluated blood samples of patients with head and neck cancer and found no significant difference in expression of microRNA-155 and microRNA-146a between the cancer patients and healthy controls [26]. Based on Yan et al. study that revealed similarities in the distributions of the saliva and plasma proteomes by Gene ontology analysis [36], we can conclude that these results in the blood that were proven in the Lerner et al. study [26] can be agreed with the results of our study in the saliva. They concluded that considering the role of biomarkers in proliferation and migration of tumor cells, expression of these biomarkers may be used as an indicator of prognosis of head and neck cancer.

Expression of microRNA-155 in OSCC has been previously investigated. Gombos et al., and Emami et al. found over-expression of this biomarker in tissue and serum samples of OSCC patients [37, 38]. Meng Wu et al. revealed that ARID2 is a target gene of microRNA-155-5p and the loss of ARID2 expression in OSCC patients significantly correlated with poor survival [39]. Lin et al. stated that microRNA-146a expression in swabbed collectives enables the differentiation between normal mucosa and OPMD/OSCC, independent of their histopathological severity [40]. The present results also revealed over-expression of microRNA-155 in OSCC patients compared with healthy controls; however, this increase was not significant. Variations in the results may be due to the assessment of microRNA molecules extracellularly and in the saliva compared with their intracellular assessment in tissue and blood cells.

Relatively small sample size due to COVID-19 pandemic was a limitation of this study. To overcome this limitation, we had to use the samples from the study by Mehdipour et al., [22] and thus, we could not change the eligibility criteria, which was another limitation of this study. A larger sample size may yield more significant results. Further studies with larger sample size are required to confirm the present results. Also, future studies may evaluate both saliva and serum samples of patients to obtain more reliable results and can focus on the correlation between the biomarkers and histological findings.

Conclusion

Considering the altered expression of microRNA-146a and microRNA-155 in dysplastic OLP and OSCC, their altered expression may be used as an alarming sign of malignancy. However, further investigations are still required.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

microRNAs:

Micro ribonucleic acids

OLP:

Oral lichen planus

OSCC:

Oral squamous cell carcinoma

RT-qPCR:

Real-time quantitative polymerase chain reaction

References

  1. Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis. 2008;14(3):229–43.

    Article  PubMed  Google Scholar 

  2. Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):72–80.

    Article  PubMed  Google Scholar 

  3. González-Moles M, Warnakulasuriya S, González-Ruiz I, Ayén Á, González-Ruiz L, Ruiz-Ávila I, et al. Dysplasia in oral lichen planus: relevance, controversies and challenges. A position paper. Med Oral Patol Oral Cir Bucal. 2021;26(4):e541–e8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Arão TC, Guimarães AL, de Paula AM, Gomes CC, Gomez RS. Increased miRNA-146a and miRNA-155 expressions in oral lichen planus. Arch Dermatol Res. 2012;304(5):371–5.

    Article  PubMed  Google Scholar 

  5. Ma H, Wu Y, Yang H, Liu J, Dan H, Zeng X, et al. MicroRNAs in oral lichen planus and potential miRNA-mRNA pathogenesis with essential cytokines: a review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(2):164–73.

    Article  PubMed  Google Scholar 

  6. Setién-Olarra A, Gainza-Cirauqui ML, Aguirre-Urizar JM, Marichalar-Mendia X. The role of microRNAs in oral lichenoid disorders. Systematic review. Med Oral Patol Oral Cir Bucal. 2017;22(5):e548–e53.

    PubMed  PubMed Central  Google Scholar 

  7. Gupta S, Jawanda MK. Oral Lichen Planus: an update on etiology, pathogenesis, clinical presentation, diagnosis and management. Indian J Dermatol. 2015;60(3):222–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Tao Y, Ai R, Hao Y, Jiang L, Dan H, Ji N, et al. Role of miR-155 in immune regulation and its relevance in oral lichen planus. Exp Ther Med. 2019;17(1):575–86.

    PubMed  Google Scholar 

  9. Mashima R. Physiological roles of miR-155. Immunology. 2015;145(3):323–33.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A. Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. J Biol Chem. 2013;288(1):608–18.

    Article  PubMed  Google Scholar 

  11. Yang JG, Sun YR, Chen GY, Liang XY, Zhang J, Zhou G. Different expression of MicroRNA-146a in Peripheral Blood CD4(+) T cells and lesions of oral Lichen Planus. Inflammation. 2016;39(2):860–6.

    Article  PubMed  Google Scholar 

  12. Ikehata N, Takanashi M, Satomi T, Watanabe M, Hasegawa O, Kono M, et al. Toll-like receptor 2 activation implicated in oral squamous cell carcinoma development. Biochem Biophys Res Commun. 2018;495(3):2227–34.

    Article  PubMed  Google Scholar 

  13. Gissi DB, Morandi L, Gabusi A, Tarsitano A, Marchetti C, Cura F, et al. A noninvasive test for MicroRNA expression in oral squamous cell carcinoma. Int J Mol Sci. 2018;19(6):1789.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mazumder S, Datta S, Ray JG, Chaudhuri K, Chatterjee R. Liquid biopsy: miRNA as a potential biomarker in oral cancer. Cancer Epidemiol. 2019;58:137–45.

    Article  PubMed  Google Scholar 

  15. Huffaker TB, Hu R, Runtsch MC, Bake E, Chen X, Zhao J, et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep. 2012;2(6):1697–709.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ahmadi-Motamayel F, Bayat Z, Hajilooi M, Shahryar-Hesami S, Mahdavinezhad A, Samie L, et al. Evaluation of the miRNA-146a and miRNA-155 expression levels in patients with oral Lichen Planus. Iran J Immunol. 2017;14(4):316–24.

    PubMed  Google Scholar 

  17. Cheng YS, Rees T, Wright J. A review of research on salivary biomarkers for oral cancer detection. Clin Transl Med. 2014;3(1):3.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Arantes L, De Carvalho AC, Melendez ME, Lopes Carvalho A. Serum, plasma and saliva biomarkers for head and neck cancer. Expert Rev Mol Diagn. 2018;18(1):85–112.

    Article  PubMed  Google Scholar 

  19. Rezapour A, Jahangiri R. The economic burden of oral cancer in Iran. 2018;13(9):e0203059.

  20. Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran J Public Health. 2018;47(3):309–16.

    PubMed  PubMed Central  Google Scholar 

  21. Mayr FB, Spiel AO, Leitner JM, Firbas C, Kliegel T, Jilma B. Ethnic differences in plasma levels of interleukin-8 (IL-8) and granulocyte colony stimulating factor (G-CSF). Transl Res. 2007;149(1):10–4.

    Article  PubMed  Google Scholar 

  22. Mehdipour M, Shahidi M, Manifar S, Jafari S, Mashhadi Abbas F, Barati M, et al. Diagnostic and prognostic relevance of salivary microRNA-21, -125a, -31 and – 200a levels in patients with oral lichen planus - a short report. Cell Oncol (Dordr). 2018;41(3):329–34.

    Article  PubMed  Google Scholar 

  23. Tap J, Cools-Portier S, Pavan S, Druesne A, Öhman L, Törnblom H, et al. Effects of the long-term storage of human fecal microbiota samples collected in RNAlater. Sci Rep. 2019;9(1):601.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci. 1993;694:72–7.

    Article  PubMed  Google Scholar 

  25. Wang L, Wu W, Chen J, Li Y, Xu M, Cai Y. MicroRNA microarray-based identification of involvement of miR-155 and miR-19a in development of oral Lichen Planus (OLP) by modulating Th1/Th2 balance via Targeting eNOS and Toll-Like receptor 2 (TLR2). Med Sci Monit. 2018;24:3591–603.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lerner C, Wemmert S, Bochen F, Kulas P, Linxweiler M, Hasenfus A, et al. Characterization of miR-146a and miR-155 in blood, tissue and cell lines of head and neck squamous cell carcinoma patients and their impact on cell proliferation and migration. J Cancer Res Clin Oncol. 2016;142(4):757–66.

    Article  PubMed  Google Scholar 

  27. Liang XY, Hu JY, Zhou G. [Detection of miR-155, miR-146a in PBNCs and tissues from patients with oral lichen planus]. Shanghai Kou Qiang Yi Xue. 2015;24(6):729–34.

    PubMed  Google Scholar 

  28. Momen-Heravi F, Trachtenberg AJ, Kuo WP, Cheng YS. Genomewide Study of salivary MicroRNAs for detection of oral Cancer. J Dent Res. 2014;93(7 Suppl):86s–93s.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Hooks JJ, Redmond TM. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun. 2010;402(2):390–5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008;10(4):R101.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sonkoly E, Ståhle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol. 2008;18(2):131–40.

    Article  PubMed  Google Scholar 

  32. Wang J, Yang L, Wang L, Yang Y, Wang Y. Forkhead box p3 controls progression of oral lichen planus by regulating microRNA-146a. J Cell Biochem. 2018;119(11):8862–71.

    Article  PubMed  Google Scholar 

  33. Liu F, Wu J, Ye F. [Expression of miRNA-155 and miRNA-146a in peripheral blood mononuclear cells and plasma of oral lichen planus patients]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2015;50(1):23–7.

    PubMed  Google Scholar 

  34. Witten LW, Cheng CJ, Slack FJ. miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene. 2019;38(12):2151–61.

  35. Tili E, Michaille JJ, Croce CM. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev. 2013;253(1):167–84.

    Article  PubMed  Google Scholar 

  36. Yan W, Apweiler R, Balgley BM, Boontheung P, Bundy JL, Cargile BJ et al. Systematic comparison of the human saliva and plasma proteomes. Proteom Clin Appl 2009 Jan 1;3(1):116–34.

  37. Emami N, Mohamadnia A, miR-155. miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers. 2020;46(5):341–7.

  38. Gombos K, Horváth R, Szele E, Juhász K, Gocze K, Somlai K, et al. miRNA expression profiles of oral squamous cell carcinomas. Anticancer Res. 2013;33(4):1511–7.

    PubMed  Google Scholar 

  39. Wu M, Duan Q, Liu X, Zhang P, Fu Y, Zhang Z, Liu L, Cheng J, Jiang H. MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2. Biomedicine & Pharmacotherapy. 2020 Feb 1;122: 109696.

  40. Lin SC, Liu CJ, Ji SH, Hung WW, Liu YC, Chang SR, et al. The upregulation of oncogenic miRNAs in swabbed samples obtained from oral premalignant and malignant lesions. Clin Oral Investig. 2022 Feb;26(2):1343–51.

Download references

Acknowledgements

This study was based on a postgraduate thesis accomplished by Homa Mirzaei under the supervision of Dr. Masoumeh Mehdipour and Dr. Minoo Shahidi in the academic year of 2021–2022 at the Faculty of Dentistry, Shahid Beheshti University of Medical Sciences. The authors are greatly thankful to the staff members of oral medicine department for their utmost cooperation.

Funding

None.

Author information

Authors and Affiliations

  1. Oral Medicine Department, School of Dentistry, Shahid Beheshti University of Medical Sciences, Daneshjoo Blvd, Evin, Chamran high way, Tehran, 1983963113, Iran

    Masoumeh Mehdipour, Fahimeh Anbari, Homa Mirzaei & Soudeh Jafari

  2. Hematology and blood banking Department, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

    Minoo Shahidi

  3. Department of Medical Biotechnology, Faculty of Allied Medical Science, Iran University of Medical Sciences, Tehran, Iran

    Azam Kholghi & Ehsan Lotfi

  4. Oral Medicine Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

    Soheila Manifar

  5. Oral Pathology Department, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Fatemeh Mashhadiabbas

Authors
  1. Masoumeh Mehdipour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Minoo Shahidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fahimeh Anbari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Homa Mirzaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soudeh Jafari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Azam Kholghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ehsan Lotfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Soheila Manifar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fatemeh Mashhadiabbas
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.M. and M.SH. designed the study. H.M., F.A., S.J., and S.M. contributed to clinical studies. A.KH., E.L., and F.M. performedexperimental studies. H.M. performed data acquisition and data analysis. H.M. wrote the manuscript. M.M. and M.SH. supervised the study. All authors reviewed and revised the manuscript. All authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Corresponding author

Correspondence to Homa Mirzaei.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by the ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.DRC.REC.1399.044). Written informed consent was obtained from all patients to use their information and biopsy samples for research purposes. The authors confirm that this study complies with all relevant guidelines and regulations.

Consent for publication

Not Applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mehdipour, M., Shahidi, M., Anbari, F. et al. Salivary level of microRNA-146a and microRNA-155 biomarkers in patients with oral lichen planus versus oral squamous cell carcinoma. BMC Oral Health 23, 433 (2023). https://doi.org/10.1186/s12903-023-03155-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12903-023-03155-z

Keywords

BMC Oral Health

ISSN: 1472-6831

Contact us